

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**205353Orig1s000**

***Trade Name:*** FARYDAK

***Generic Name:*** panobinostat

***Sponsor:*** Novartis Pharmaceuticals Corporation

***Approval Date:*** February 23, 2015

***Indications:*** This new drug application provides for the use of FARYDAK® (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (Dex), for the treatment of patients with multiple myeloma (MM), who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 205353Orig1s000

### CONTENTS

#### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	<b>X</b>
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	<b>X</b>
<b>Cross Discipline Team Leader Review</b>	<b>X</b>
<b>Medical Review(s)</b>	<b>X</b>
<b>Chemistry Review(s)</b>	<b>X</b>
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	<b>X</b>
<b>Microbiology / Virology Review(s)</b>	<b>X</b>
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	<b>X</b>
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**205353Orig1s000**

**APPROVAL LETTER**



NDA 205353

**ACCELERATED APPROVAL**

Novartis Pharmaceuticals Corporation  
Attention: Ms. Jeannie Shen  
Sr. Associate Director, Drug Regulatory Affairs  
One Health Plaza  
East Hanover, NJ 07936-1080

Dear Ms. Shen:

Please refer to your New Drug Application (NDA) dated March 22, 2014, received March 24, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for FARYDAK<sup>®</sup> (panobinostat) 10 mg, 15 mg, and 20 mg capsules.

We acknowledge receipt of your amendments dated April 3, and 29, 2014; May 6 (2), 7 (2), 15 (2), 21 (3), and 29, 2014; June 2, 5, 20, 23 (2), 26, and 27 (2), 2014; July 2, 3, 10, 11, 15, 24, 25, 28, and 31, 2014; August 7 (2), 12, 13, 18, 20 (2), 21, 26, 27, and 29, 2014; September 5, 8, and 18 (2), 2014; October 7, 14 (2), 15, 27, and 29, 2014; December 3, 8, 11, 15 and 16, 2014; January 9, 12, 13, 15, 28, and 30, 2015; and February 4, 6, 9, 19, and 20, 2015.

This new drug application provides for the use of FARYDAK<sup>®</sup> (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (Dex), for the treatment of patients with multiple myeloma (MM), who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved under the provisions of accelerated approval regulations (21 CFR 314.500), effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text. Marketing of this drug product and related activities must adhere to the substance and procedures of the referenced accelerated approval regulations.

We note that your February 19, 2015, submission includes final printed labeling (FPL) for your package insert and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND IMMEDIATE CONTAINER LABELS**

We acknowledge your February 19, 2015, submission containing final printed carton and container labels.

## **ACCELERATED APPROVAL REQUIREMENTS**

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled studies/clinical trials to verify and describe clinical benefit. You are required to conduct such studies/clinical trials with due diligence. If postmarketing studies/clinical trials fail to verify clinical benefit or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530, withdraw this approval. We remind you of your postmarketing requirement specified in your submission dated February 19, 2015. These requirements, along with required completion dates, are listed below.

### **PMR 2181-1**

Conduct a randomized Phase 2 clinical trial of panobinostat in combination with subcutaneous bortezomib and dexamethasone to characterize the safety and efficacy of at least two different doses of panobinostat. Eligible patients will include patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents. The primary objective is to assess the overall response rate (ORR) in all treatment arms according to International Myeloma Working Group (IMWG) criteria by investigator assessment. The trial should include one interim analysis. The results of this trial will be used to inform the dose selection for the confirmatory Phase 3 trial. Submit a final report with full datasets.

Preliminary Protocol Submission to Include SAP:	04/2015
Final Protocol Submission:	09/2015
Interim Analysis:	08/2017
Trial Completion:	08/2018
Final Report Submission:	08/2019

### PMR 2181-2

Conduct a multicenter, randomized, placebo-controlled Phase 3 trial comparing panobinostat in combination with subcutaneous bortezomib and dexamethasone with subcutaneous bortezomib and dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents. The panobinostat dose selection will be based upon the interim analysis of the trial described in PMR 2181-1. Eligible patients will have previously treated multiple myeloma, 1-3 prior lines of therapy, prior immunomodulatory agent exposure (either thalidomide, lenalidomide, or pomalidomide), and measurable disease. The primary objective is to compare the progression free survival (PFS) in both treatment arms by investigator assessment.

Preliminary Protocol Submission to Include SAP:	03/2017
Final Protocol Submission:	11/2017
Trial Completion:	02/2021
Final Report Submission:	12/2021

Submit clinical protocols to your IND 069862 for this product. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each requirement in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial.

Submit final reports to this NDA as a supplemental application. For administrative purposes, all submissions relating to this postmarketing requirement must be clearly designated “**Subpart H Postmarketing Requirement(s).**”

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

### **RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

Section 505-1 of the FDCA authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)]. The details of the REMS requirements were outlined in our REMS notification letter dated February 4, 2015.

Your proposed REMS, submitted on February 20, 2015, and appended to this letter, is approved. The REMS consists of a communication plan and a timetable for submission of assessments of the REMS.

Your REMS must be fully operational before you introduce FARYDAK<sup>®</sup> (panobinostat) into interstate commerce.

The REMS assessment plan should include, but is not limited to, the following:

1. Launch date of FARYDAK<sup>®</sup>
2. An evaluation of healthcare providers who prescribe or dispense awareness and understanding of the risks associated with FARYDAK<sup>®</sup> (panobinostat) and the management of these events:
  - Severe diarrhea
  - Severe and fatal cardiac ischemic events
  - Severe arrhythmias
  - ECG changes
3. A description of the implementation of the communication plan, including:
  - Number of healthcare providers and professional societies targeted by the REMS.
  - Number of REMS letters sent to healthcare providers and professional societies via email, standard mail, and facsimile, and the dates the letters were sent. Include the number of letters sent via mail because the emailed letter was undeliverable. Also include numbers of returned or undeliverable letters. For letters sent via email, include the number of letters successfully delivered, and number of email letters opened by the recipients.
  - Which professional societies distributed the REMS letters or content of the letter to their membership.
  - The sources of the distribution lists.
  - Date journal pieces appeared in each journal or publication, including volume, issue number, and journal name.
  - Date and name of the scientific meetings attended and materials displayed.
  - Date the REMS website went live, and number of unique site visits to the FARYDAK<sup>®</sup> (panobinostat) REMS website during the assessment period.
  - Number of REMS fact sheets distributed by Novartis representatives during follow-up details/visits with healthcare providers during the 12 months after approval of the REMS.

The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether 1 or more such goals or such elements should be modified.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of the FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 205353 REMS CORRESPONDENCE  
(insert concise description of content in bold capital letters, e.g.,  
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT  
METHODOLOGY)**

Prominently identify the submission containing the REMS assessments or proposed modifications with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 205353 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 205353  
PROPOSED REMS MODIFICATION**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)  
FOR NDA 205353  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

### **PROMOTIONAL MATERIALS**

Under 21 CFR 314.550, you are required to submit, during the application pre-approval review period, all promotional materials, including promotional labeling and advertisements, that you intend to use in the first 120 days following marketing approval (i.e., your launch campaign). If you have not already met this requirement, you must immediately contact the Office of Prescription Drug Promotion (OPDP) at (301) 796-1200. Please ask to speak to a regulatory project manager or the appropriate reviewer to discuss this issue.

As further required by 21 CFR 314.550, submit all promotional materials that you intend to use after the 120 days following marketing approval (i.e., your post-launch materials) at least 30 days before the intended time of initial dissemination of labeling or initial publication of the advertisement. We ask that each submission include a detailed cover letter together with three copies each of the promotional materials, annotated references, and approved package insert (PI)/Medication Guide/patient PI (as applicable).

Send each submission directly to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotions (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

### **METHODS VALIDATION**

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

### **MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at

<http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm>.

## **POST APPROVAL FEEDBACK MEETING**

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

## **PDUFA V APPLICANT INTERVIEW**

FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs under PDUFA V ('the Program'). The PDUFA V Commitment Letter states that these assessments will include interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a PDUFA V applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

If you have any questions, call CAPT Diane Hanner, Regulatory Project Manager, at (301) 796-4058.

Sincerely,

*{See appended electronic signature page}*

Richard Pazdur, M.D.  
Director  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

### ENCLOSURES:

Content of Labeling  
Carton and Container Labeling  
REMS

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RICHARD PAZDUR  
02/23/2015